A single high dose of creatine monohydrate, given to healthy adults kept awake for roughly 21 hours, improved cognitive performance and boosted cerebral high-energy phosphates in a double-blind, randomized, balanced crossover trial of 15 participants. At the same time, separate long-term studies in college athletes and type 2 diabetic patients found no impairment of kidney function from creatine supplementation. Together, these findings sharpen a practical question for shift workers, medical residents, and students pulling all-nighters: can a cheap, legal supplement protect thinking under sleep loss without harming the kidneys?
Why kidney safety and brain benefits collide in 2026
Creatine monohydrate is one of the most widely used sports supplements in the world, yet persistent fears about kidney damage have kept many people away from it. The concern is not baseless on its face: creatine breaks down into creatinine, a waste product that doctors use as a proxy for kidney health. Higher creatinine readings after supplementation can trigger alarm in routine blood work, even when the kidneys are functioning normally. The sports nutrition society addressed this directly in its position stand on creatine safety and efficacy, noting that creatine may raise serum creatinine without evidence of reduced kidney function in studied populations.
That distinction matters because interest in creatine’s cognitive effects is growing fast. A crossover trial in Scientific Reports tested a single oral dose of 0.35 g/kg creatine monohydrate against placebo in 15 healthy adults during approximately 21 hours of sleep deprivation. Participants completed repeated cognitive tests alongside phosphorus-31 magnetic resonance spectroscopy (31P-MRS) brain imaging. The creatine condition showed improved cognitive performance and measurable increases in cerebral high-energy phosphates, the molecular fuel neurons burn during demanding mental tasks.
This was not the first time researchers paired creatine with sleep loss. An earlier human experiment combined creatine supplementation with sleep deprivation and mild exercise, then measured cognition, psychomotor performance, mood, and stress hormones including catecholamines and cortisol. That trial also found preserved psychomotor speed and mood in the creatine condition, establishing a pattern that has now been replicated with brain-imaging confirmation and a more direct focus on cerebral energy metabolism.
Kidney data from athletes and diabetic patients
The strongest renal safety evidence comes from populations where kidney stress would be most likely to surface. A 21‑month study of Division IA football players tracked repeated panels of blood and urine clinical markers, including renal-function indicators, comparing creatine users against non-users over time. The study found no significant effect on clinical markers of health. Because these athletes trained at extreme intensities while supplementing daily, the results carry weight for recreational users taking smaller doses.
Even more telling is the evidence from a higher-risk clinical group. A 12‑week placebo-controlled trial in type 2 diabetes assessed kidney function with filtration markers and found no impairment from creatine supplementation. Type 2 diabetes already stresses the kidneys, so the absence of harm in this population is a stronger signal than results from healthy young athletes alone. The U.S. Food and Drug Administration’s GRAS Notice (GRN) No. 931 for creatine monohydrate compiles these and other human trials with renal endpoints into structured evidence tables supporting a “generally recognized as safe” conclusion for use in foods at commonly consumed doses.
Additional reassurance comes from a broader clinical picture. A recent review of creatine and kidney outcomes surveyed randomized trials and observational cohorts, concluding that standard oral doses do not appear to accelerate kidney damage in people without pre-existing advanced renal disease. Across studies, transient bumps in serum creatinine were common, but they reflected the extra creatine load rather than a true drop in filtration capacity.
Gaps between the brain trials and the kidney data
The cognitive and renal evidence, while individually strong, have not yet been tested together in a single protocol. The sleep-deprivation crossover trial used a high single dose of 0.35 g/kg, which for an 80 kg person translates to 28 grams in one sitting. That is well above the 3 to 5 gram daily maintenance dose most athletes use and higher than the typical 20‑gram loading regimens spread across a day. No published trial has measured serum creatinine or cystatin C specifically during this acute high-dose cognitive protocol. The long-term safety cohorts tracked kidney markers over weeks or months of daily use, not after a single large bolus designed to flood the brain with phosphocreatine before a night shift.
A related open question is whether a smaller single dose, below 0.35 g/kg, could still raise prefrontal phosphocreatine enough to preserve working memory after 24 hours of sleep loss. If a lower dose works, it would reduce the gastrointestinal discomfort some people experience with large creatine loads and further minimize any theoretical renal signal. But no trial has tested that threshold yet, leaving a gap between the dose researchers know works for the brain and the dose range where kidney safety data is most abundant.
Another limitation is that most kidney-focused trials rely on conventional markers such as serum creatinine, estimated glomerular filtration rate, and occasional urinary protein checks. These are excellent for detecting moderate to severe dysfunction but less sensitive to very subtle tubular changes that might emerge under extreme dosing or in vulnerable subgroups. Advanced imaging, novel biomarkers, and longer follow-up would be needed to rule out small effects of very high acute doses with confidence.
What this means for real-world use
For now, the evidence supports a cautious but optimistic middle ground. Standard creatine regimens-around 3 to 5 grams per day, with or without a short loading phase-appear safe for kidney function in healthy people and even in some individuals with early metabolic disease, while offering potential benefits for muscle performance and, in some contexts, cognition. The sleep-deprivation data suggest that higher single doses can acutely support brain energy and performance when rest is restricted, but those protocols have not been paired with detailed renal monitoring.
People considering creatine as a buffer against night shifts or exam cramming should weigh several practical points. First, no supplement can fully compensate for chronic sleep loss; the trials examined short-term deprivation in otherwise healthy adults, not years of rotating shift work. Second, individual responses vary: some users experience bloating or gastrointestinal upset at higher doses, which may be unacceptable in high-stakes settings like surgery or emergency response. Third, anyone with known kidney disease, uncontrolled hypertension, or complex medication regimens should discuss creatine use with a clinician familiar with their history and the current evidence base.
For researchers, the next step is clear. A trial that combines the high-dose cognitive protocol with rigorous kidney monitoring-using both traditional markers and newer biomarkers-would directly address lingering safety questions. Dose-ranging studies could clarify the minimum effective amount for preserving cognition under sleep loss, allowing guidelines to converge on doses that are both brain-effective and comfortably within established renal safety margins.
Until those data arrive, creatine remains a promising but imperfect tool: one of the best-studied sports supplements, increasingly supported for certain cognitive applications, and generally reassuring for kidney health at typical doses-yet still missing the final piece of evidence that would definitively link its brain benefits and renal safety in the exact scenarios where sleep is scarce and mental performance matters most.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
